Clinical Trials Logo
  1. Home
  2. Polycystic Kidney Disease, Adult
  3. NCT04152837

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease — ALERT  

ADPKD Clinical Trial

Official title:
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study

Clinical Trial Summary

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible participants will be enrolled and treated with lixivaptan for 52 weeks following titration to an optimal dose.

Clinical Trial Description

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 participants will be enrolled and treated. Evaluations will include frequent testing of liver chemistry (every week during the Baseline and Titration Periods and every 4 weeks during the Maintenance Period), physical examinations, vital signs, safety labs (serum chemistry, hematology, urinalysis), estimated glomerular filtration rate (eGFR), urine specific gravity and osmolality determinations and trough serum concentration of lixivaptan. After meeting entry criteria during a 1- to 3-week Screening Period that can extend up to 8 weeks for medication adjustment, participants will enter a 3-week no study treatment Baseline Period to obtain baseline measurements followed by a 3- to 6-week Titration Period during which lixivaptan administered twice daily (BID) will be titrated to a dose that is tolerated and results in a reduced trough urine specific gravity, or to the maximum dose level. The minimum dose to enter the Maintenance Period is 100 mg BID. Treatment will continue for up to 52 weeks (12 months) after which study drug will be held, and final assessments obtained during the Follow-up Period of 4 weeks. The total study duration will be up to approximately 73 weeks (16.8 months). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04152837
Study type Interventional
Source Palladio Biosciences
Contact
Status Terminated
Phase Phase 3
Start date September 2, 2020
Completion date July 29, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT02776241 - Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03203642 - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Phase 2
Recruiting NCT04338048 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Not yet recruiting NCT06100133 - Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? Phase 2
Completed NCT01632605 - The Vienna RAP Pilot Study N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Not yet recruiting NCT05373264 - HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life Phase 3
Recruiting NCT06085807 - Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Completed NCT01853553 - Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT04472624 - Short Term Induction of Ketosis in PKD N/A
Not yet recruiting NCT03764605 - Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT04680780 - Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT02161068 - Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4
Completed NCT00345137 - Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis Phase 1